The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable excitement within the market. A shift away from Schedule I status, often regarded as outdated and hindering https://royalbookmarking.com/story20723491/cannabinoid-rescheduling-a-growth-catalyst